Primary cilia are required for vertebrate cells to respond to specific intercellular signals. Here we define when and where primary cilia appear in the mouse embryo using a transgenic line that expresses ARL13B-mCherry in cilia and Centrin 2-GFP in centrosomes. Primary cilia first appear on cells of the epiblast at E6.0 and are subsequently present on all derivatives of the epiblast. In contrast, extraembryonic cells of the visceral endoderm and trophectoderm lineages have centrosomes but no cilia. Stem cell lines derived from embryonic lineages recapitulate the in vivo pattern: epiblast stem cells are ciliated, whereas trophoblast stem cells and extraembryonic endoderm (XEN) stem cells lack cilia. Basal bodies in XEN cells are mature and can form cilia when the AURKA-HDAC6 cilium disassembly pathway is inhibited. The lineage-dependent distribution of cilia is stable throughout much of gestation, defining which cells in the placenta and yolk sac are able to respond to Hedgehog ligands.
embryos ( Fig. 1a,b ). Small puncta of ARL13B-mCherry were detected adjacent to the centrosomes in about 2% of ICM cells in blastocysts with 64-100 cells ( Fig. 1c,d , arrow; two puncta/107 cells scored from nine embryos; Supplementary Video 2), but these puncta did not show cilium morphology and did not express the cilium marker acetylated α-tubulin ( Supplementary Fig. 1M ). No ARL13B-mCherry expression was detected in trophectoderm cells at this stage ( Fig. 1c ; 0/255 cells from nine embryos).
Cilia were first detected after implantation on epiblast cells, at the time of cavitation (embryonic day 5.5, E5.5). At this stage, elongated ARL13B-mCherry cilia adjacent to Centrin 2-GFP centrioles were detected in a small fraction (<1%) of epiblast cells ( Fig. 1e ,f; 3/654 epiblast cells from 10 embryos; Supplementary Video 3). By E6.0, elongated ARL13B-mCherry+ primary cilia were present on 32.7 ± 7.3% epiblast cells ( Fig. 1g ,h, arrows; 388/1039 epiblast cells from six embryos; Supplementary Video 4). At E8.0, mCherry+ primary cilia were detected on all non-dividing epiblast-derived cells of the three germ layers, ectoderm, mesoderm and definitive endoderm (Fig. 1i,j and Supplementary Video 5), including cells of the embryonic node (Fig. 1k) . At mid-gestation (e10.5), mCherryexpressing cilia projected from Centrin 2-GFP+ centrioles in cells throughout the embryo, including limb mesenchyme ( Fig. 1l ) and neural epithelial cells (Fig. 1m) .
In contrast to the presence of primary cilia on epiblast cells at E6.0, cilia were never detected on cells of extraembryonic lineages, the visceral endoderm ( Fig. 1h , asterisk) or extraembryonic ectoderm (0/837 cells from six embryos, ∼140 cells analysed/embryo). Antibody staining confirmed that primary cilia positive for ARL13B and IFT88 (intraflagellar transport 88) were present only on epiblast cells and not cells of the visceral endoderm in E6.0 embryos ( Supplementary  Fig. 1N ,O; 0/659 cells from five embryos, ∼130 cells per embryo). The presence of primary cilia on epiblast cells and not on extraembryonic lineages was particularly striking in the E7.5 endoderm, which is composed of two intermixed populations, the embryonic visceral endoderm, which is derived from the extraembryonic lineage of the primitive endoderm and expresses alpha fetoprotein (AFP), and definitive endoderm, which is derived from cells of the epiblast that have gastrulated through the primitive streak 11, 12 . At E6.5, before gastrulation has begun, AFP-GFPexpressing visceral endoderm cells form a continuous layer of cells on the outside of the embryo, but no ARL13B-mCherry-labelled cilia were detected on AFP-GFP+ cells ( Fig. 2a-c) , although cilia were clearly present on epiblast cells ( Fig. 2c , arrow). Once gastrulation began, ciliated definitive embryonic endoderm cells intercalated into the outer layer between the AFP-GFP+ extraembryonic visceral endoderm cells ( Fig. 2d-f ). By early bud stages (E7.5), most of the endodermal layer of the embryo was composed of streak-derived definitive endoderm cells and these cells were ciliated, whereas the AFP-GFP-expressing cells in the endoderm layer still lacked ARL13B-mCherry+ primary cilia ( was determined by their cell lineage and not by their position in the embryo. At E8.0, there were still no ARL13B-mCherry+ cilia detectable on cells derived from the trophoblast lineage (ectoplacental cone and extraembryonic ectoderm; Fig. 2j -l) or the extraembryonic visceral endoderm ( Fig. 2m ,n).
Lineage specific assembly of primary cilia persists through gestation
The absence of cilia from the trophoblast and visceral endoderm lineages persisted later in gestation. In the labyrinth layer of the E14.5 placenta, no ARL13B+ primary cilia were detected on syncytiotrophoblast cells of the trophoblast lineage ( Fig. 3a -c, arrowheads), whereas epiblast-derived cells that surround the fetal blood vessels were ciliated ( Fig. 3d , arrows). The yolk sac includes cells derived from both the extraembryonic visceral endoderm and the epiblast-derived mesoderm. At E14.5, ARL13B-mCherry+ primary cilia were present on 57.4 ± 8.1% of mesoderm-derived mesothelial cells ( Fig. 3e arrow, g arrows; 221/386 cells from two embryos) and 33.4 ± 3.1% of mesoderm-derived endothelial cells ( Fig. 3f ,g arrowheads; 95/292 cells from two embryos) that surrounded the blood vessels in the yolk sac, labelled with PECAM1 (platelet/endothelial cell adhesion molecule 1) ( Fig. 3g ). In contrast, no ARL13B-mCherry+ cilia were seen associated with Centrin 2-GFP+ centrosomes in the cells of the extraembryonic-visceral-endodermderived layer of yolk sac cells ( Fig. 3f ,g triangles; 0/1032 cells from two embryos).
Stem cell lines stably recapitulate the in vivo pattern of ciliogenesis
Stem cell lines that stably retain the developmental potential of each of the lineages of the early mouse embryo can be derived and maintained in culture 13 ; we therefore tested whether the lineage dependence of cilium formation was reflected in these stem cell lines. We derived mouse embryonic stem cells (mESCs) from double transgenic embryos under 2i+LIF (leukemia inhibitory factor) conditions that promote ground state pluripotency 14 and observed that 18% of mESCs were ciliated ( Fig. 4a ), similar to previous results in standard mESC conditions 15 . Trophoblast stem cells (TSCs) and extraembryonic endoderm (XEN) stem cells retain the ability to differentiate into the trophoblast derivatives of the placenta 16 and extraembryonic endoderm derivatives 17 , respectively, in chimeras. TSCs, marked by expression of EOMES 18 , were not ciliated, as shown by lack of acetylated α-tubulin+ structures adjacent to γ-tubulin+ centrosomes ( Fig. 4b and Supplementary Fig. 2A-D) . In XEN cells derived from ARL13B-mCherry Centrin 2-GFP transgenic embryos, no focal ARL13B-mCherry was detected adjacent to Centrin 2-GFP+ centrosomes ( Fig. 4c ), even though western blotting showed that ARL13B-mCherry was expressed in these cells ( Supplementary  Fig. 2I ). Antibody staining for ARL13B or acetylated α-tubulin confirmed that XEN cells, marked by expression of SOX17, did not form primary cilia (Fig. 4d ,f-n,p-v and Supplementary Fig. 2E-H) . Epiblast stem cells (EpiSCs) represent the state of the epiblast from postimplantation embryos 19, 20 . As in the cells of the E6.5 epiblast, ARL13B immunostaining showed that almost every non-mitotic cell in EpiSC colonies was ciliated ( Fig. 4e ; 87.2 ± 8.4%). Thus there was a correlation between the presence of cilia in the embryo and in the corresponding stem cell line: primary cilia are present on embryonic epiblast and its derivatives and in EpiSCs, whereas cilia are not present on visceral endoderm or trophectoderm cells in the embryo or in XEN or TSC lines.
XEN cells are believed to be more similar to embryonic parietal endoderm than visceral endoderm 17 . We therefore added the glycogen synthase kinase 3β (GSK3β) inhibitor CHIR99201 to convert XEN cells into visceral endoderm 21 . This treatment caused upregulation of FOXA2, a visceral endoderm specific transcription factor ( Supplementary Fig. 2J ), and caused a transition from a rounded XEN cell morphology to an epithelial morphology and upregulation of E-cadherin, as in the visceral endoderm ( Supplementary Fig. 2L ). Antibody staining for acetylated α-tubulin and γ-tubulin showed that these cells lacked primary cilia ( Supplementary Fig. 2K ,M), demonstrating that visceral endoderm cells derived from XEN cells lack primary cilia, similarly to visceral endoderm cells in the embryo.
Removal of serum from many cultured cells triggers exit from the cell cycle and promotes cilium formation 2 . In contrast, withdrawal of serum from XEN cells did not lead to cilium assembly ( Fig. 4d ; 0/267 cells from two independent experiments) and the EpiSCs that formed cilia were grown in the presence of serum. Thus mechanisms that have been described in cell culture may not regulate cilium formation in embryo-derived stem cell lines.
XEN cell basal bodies are mature but do not nucleate cilia
The absence of cilia in XEN cell lines made it possible to test why cilia fail to form in this lineage. Transcription factors of the RFX family promote the expression of genes required for ciliogenesis 22 , and RFX3 is required for the formation of normal primary cilia in the mouse embryo 23 . RFX3 was highly expressed in epiblast cells and at lower levels in visceral endoderm cells ( Supplementary Fig. 3A,B) ; however, RFX3 was expressed in all nuclei in both mESCs ( Supplementary  Fig. 3C ,D) and XEN cells ( Supplementary Fig. 3E ,F), indicating that RFX3 is not the factor that determines which lineages are ciliated.
For ciliogenesis to initiate, the mother centriole must mature into a basal body with distal appendages that dock the mother centriole to the plasma membrane and subdistal appendages that mediate attachment to microtubules; after membrane attachment, proteins of the ciliary transition zone are recruited 24 . CEP164, a centrosomal distal appendage protein, and Ninein, a subdistal appendage protein, were both localized to the distal end of mother centrosomes in XEN cells (Fig. 4f,h) , as in ciliated mouse embryonic fibroblasts (MEFs) and EpiSCs (Fig. 4g,i and Supplementary Fig. 3G,H) . In cycling fibroblasts, serum withdrawal triggers the recruitment of positive regulators to the distal tip of the mother centriole, including the kinase TTBK2, which acts at the mother centriole to recruit intraflagellar transport proteins and initiate axoneme assembly 25 . Antibody staining showed that TTBK2 and IFT88 both localized to the distal end of the mother centriole in XEN cells (Fig. 4j,l) , as in ciliated MEFs and EpiSCs, where IFT88 was also present in the axoneme (Fig. 4k,m and Supplementary Fig. 3I,J) . In addition, the transition zone proteins NPHP4, MKS1, CEP290 and Inversin were present at centrioles in XEN cells (Fig. 4n,p,r,t) , as in ciliated MEFs (Fig. 4o,q,s,u) . Thus the basal bodies in XEN cells seem to be poised to make cilia.
The initiation of ciliogenesis is associated with removal of negative regulators, including CP110, from the distal tip of the mother centriole 26, 27 . In ciliated MEFs and EpiSCs, CP110 was only present on the daughter centriole and was absent from the mother centriole ( Fig. 4w and Supplementary Fig. 3K ), whereas CP110 localized to both the mother and daughter centrioles in XEN cells ( Fig. 4v ) and in cells of the embryonic visceral endoderm at E6.5 (Fig. 4x, arrows) .
We used short interfering RNA (siRNA) to partially (68%) knock down expression of CP110. In those knockdown cells where CP110 could not be detected at the centriole, cilia were not formed, as no ARL13B+ or IFT88+ axonemes were detected ( Supplementary Fig. 3P,R) . Instead, as in U2OS osteosarcoma cells 27 caused formation of elongated centrioles (16.6 ± 7.7%, 65/503 cells), distinguished by expression of γ-tubulin and Centrin 2-GFP along their length ( Supplementary Fig. 3L-R) and IFT88 at the distal end of the mother centriole ( Supplementary Fig. 3P ). Thus the presence of CP110 on centrioles does not account for the lack of cilia in XEN cells.
Recently, a number of proteins and factors, including PLK1, APC/C and ceramide, have been reported to regulate ciliogenesis in specific cell types [29] [30] [31] . We did not detect any role for these components in regulation of cilium formation in XEN cells ( Supplementary Fig. 4 ).
The cilium disassembly pathway is active in XEN cells
When a cell enters mitosis, the primary cilium is disassembled and the mother centriole is recruited to one of the poles of the mitotic spindle. The mitotic regulatory kinase Aurora kinase A (AURKA) plays an important role in cilium disassembly at mitosis 32 ; we therefore tested whether elevated activity of AURKA could be responsible for the absence of cilia in XEN cells. The total level of AURKA in XEN cells was 1.8 times that in EpiSCs (Fig. 5a,b ) and the ratio of activated AURKA to total AURKA was 2.4 times higher in XEN cells than in EpiSCs (Fig. 5b) ; thus there was 4.3 times more activated AURKA in (unciliated) XEN cells than in (ciliated) EpiSCs. Activation of AURKA depends on its association with the scaffolding protein NEDD9 (formerly HEF1; ref. 32) . Western blot and quantitative PCR analyses showed that NEDD9 protein levels were 2.6 ± 1.2 times higher in XEN cells than in EpiSCs (Fig. 5c,d) and Nedd9 messenger RNA levels were ∼3.6 times higher (Fig. 5e ), consistent with higher levels of active AURKA.
Blocking the cilium disassembly pathway permits cilium assembly in extraembryonic cells
To test whether lack of primary cilia on XEN cells was caused by increased AURKA activity, we cultured XEN cells in the presence of the AURKA inhibitor alisertib (MLN8237; ref. 33 ). Treatment with 250 nM alisertib for 16 h reduced levels of phosphorylated AURKA by 32.5-fold (Fig. 6a) , and active AURKA could no longer be detected at the spindle pole ( Supplementary Fig. 5A-F) . After drug treatment, 6.6 ± 2.7% of XEN cells were ciliated (20/328 cells, n = 328 cells pooled from two independent experiments), compared with 0% in dimethylsulphoxide (DMSO)-treated control cells (0/392 cells, n = 392 cells pooled from two independent experiments; P < 0.0001 from t-test). Removal of serum did not increase the number of cilia assembled (6.03 ± 1.5% cilia; 15/256 cells, n = 256 cells pooled from two independent experiments, DMSO control 0/215 cells, n = 215 cells pooled from two independent experiments; P < 0.0001 from t-test). Treatment with 5 µM PHA-680632, a second, albeit less specific, AURKA inhibitor, induced formation of primary cilia on 5.1 ± 1.7% of XEN cells (15/302 cells, n = 302 cells pooled from three independent experiments) after 72 h, compared with 0% in DMSO-treated control cells (0/533 cells, n = 533 cells pooled from three independent experiments; P < 0.0001 from t-test). Higher doses of the inhibitors caused profound defects in mitosis and a high rate of cell death, as expected, although up to 17% of the surviving cells were ciliated (17.2 ± 0.2% 15/87 cells, n = 87 cells pooled from two independent experiments) following treatment with 10 µM PHA-680632 for 72 h (DMSO control 0/447 cells, n = 447 cells pooled from two independent experiments; P < 0.0001 from t-test). The primary cilia that formed in the presence of the inhibitors seemed to be structurally normal, with axonemes that contained acetylated microtubules and IFT88, as well as an ARL13B+ ciliary membrane ( Fig. 6c-f ). After treatment, XEN cells still expressed SOX17, indicating that AURKA inhibition had not changed the identity of the cells ( Supplementary Fig. 5G,H) .
To confirm these findings, we knocked down AURKA in XEN cells. siRNA treatment reduced total AURKA to 15% of the level present in untreated cells (Fig. 6b) , although AURKA could still be detected at the centrosome ( Supplementary Fig. 5I-N) . After knockdown, 1.2 ± 1.1% of XEN cells were ciliated ( Fig. 6g ; 7/610 cells, n = 610 cells pooled from two independent experiments), compared with 0% of cells (0/600 cells, n = 600 cells pooled from two independent experiments, P = 0.0185 from t-test) treated with a scrambled control siRNA. AURKA promotes cilium disassembly, at least in part, by activation of the tubulin deacetylase HDAC6, which deacetylates ciliary microtubules and leads to collapse of the cilium 32 . Tubacin, a specific inhibitor of HDAC6, blocks serum-induced cilium disassembly 34 . After 12 h of 5 µM tubacin treatment, cilia were detected on 1.1 ± 1.0% of XEN cells (Fig. 6h ,i; 8/717 cells), but this was not significantly different from DMSO controls (0/516 cells from three independent experiments). After 72 h of 5 µM tubacin treatment, 3.9 ± 2.3% of XEN cells (22/573 cells, n = 573 cells pooled from three independent experiments) formed a cilium ( Supplementary Fig. 5O,P) , significantly different from 0% in DMSO controls (0/433 cells, n = 433 cells pooled from three independent experiments; P < 0.0001 from t-test).
To test whether the AURKA/HDAC6 pathway regulates cilium formation in the visceral endoderm in vivo, we cultured embryos that expressed both AFP-GFP, to mark the visceral endoderm 11 , and ARL13B-mCherry, to mark cilia, in 5 µM tubacin for 12 h. This treatment effectively increased cytoplasmic microtubule acetylation ( Supplementary Fig. 5Q -T; pixel intensity: DMSO, 1; tubacin, 4.6). In tubacin-treated embryos 2.6 ± 1.9% of visceral endoderm cells were ciliated (Fig. 6k , arrow, 30/1,313 cells, n = 1,313 cells counted across seven embryos), which was significantly different from 0% in DMSO controls ( Supplementary Fig. 6J ; 0/1,263 cells, n = 1,263 cells counted across six embryos; P = 0.0065 from t-test). These experiments demonstrate that mother centrioles in XEN and visceral endoderm cells can template cilia in extraembryonic lineages in vivo when the cilium disassembly pathway is blocked.
In cystic renal disease, loss of VHL (Von Hippel-Lindau tumor suppressor) leads to loss of cilia through activation of AURKA and NEDD9 35 , when GSK3β is inactive 36 . Western blot analysis showed that VHL protein was present at equivalent levels in XEN cells and EpiSCs ( Supplementary Fig. 4A , n = 3 from two independent experiments). Thus VHL protein is not limiting for cilium formation in XEN cells. VHL regulates the stability of the α-subunit of hypoxia inducible factor (HIF)-1α and HIF-2α, which in turn can activate NEDD9 and AURKA (ref. 35 ). 24 h treatment of XEN cells with 1 µM FM19G11, which blocks the function of both HIF-1α and HIF-2α (median inhibitory concentration = 80 nM; ref. 37) did not cause cilium formation ( Supplementary Fig. 4B ,C; 0/284 cells; DMSO 0/278 cells; from two independent experiments). Thus, in XEN cells, NEDD9 and AURKA are activated by an HIF-independent pathway to inhibit cilium formation.
Discussion
Our studies show that cilium formation in vivo is controlled by stable lineage-based mechanisms. In contrast to studies in cell culture, which have focused on the formation of cilia in response to serum withdrawal, we find that stem cell lines make stem cells on the basis of their lineage: visceral endoderm and XEN cells fail to form cilia whereas embryonic epiblast and EpiSCs grow cilia, independent of the presence of serum. The basal bodies in XEN cells are mature; they contain all the tested components of the ciliary appendages and transition zone, as well as IFT88 and the cilium-initiating kinase TTBK2, but fail to grow a ciliary axoneme. The maturity of these basal bodies is demonstrated by the formation of cilia when the AURKA/HDAC6 cilium disassembly pathway is blocked. As only a relatively small fraction of XEN cells are ciliated after inhibition of AURKA/HDAC6, there could be a further, previously undescribed pathway that blocks cilium formation in XEN and visceral endoderm cells. Alternatively, it is possible that activation of the cilium disassembly pathway is sufficient to account for the absence of cilia in XEN cells, but the essential role of AURKA in mitosis prevents a straightforward test of this hypothesis. Nevertheless, the identification of stem cell lines that differentially regulate ciliogenesis provides a foundation for further dissection of the regulatory networks that control cell-type specific cilium formation in vivo.
The lineage dependence of cilia in the mouse embryo implies that cells of extraembryonic origin cannot respond to specific developmental signals; in particular, these cells must be unable to respond to Hedgehog (Hh) ligands 1 . The first time that Hh signalling is known to be active in the mouse embryo is at the beginning of gastrulation, when Indian Hedgehog (Ihh) expressed in the extraembryonic visceral endoderm signals to the adjacent extraembryonic mesoderm to promote blood island formation 38, 39 . Ihh is also expressed at later stages in yolk sac, and the only cells in the placenta that express the Hh target gene Patched1 are in the embryo-derived cells that surround the fetal blood vessels 40 . Not only do XEN cells lack cilia, they also do not express essential components of the Hh signal transduction pathway, including PTCH1, SMO and GLI transcription factors 20, 38, 41 ; thus it seems that visceral endoderm cells are programmed in several ways to prevent responses to the Hh ligands that they produce. The data suggest that normal development of the placenta and yolk sac depends on preventing Hh target gene expression in extraembryonic lineages.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3091
M E T H O D S
METHODS Mouse strains. The species used here was Mus musculus. To generate ARL13B-mCherry transgenics, the coding region of an Arl13b complementary DNA was fused in-frame upstream of mCherry then inserted into pCAGGs, which contains a chicken β-actin promoter and cytomegalovirus immediate early enhancer 42 . The resulting pCAG-ARL13b:mCherry construct was linearized, purified and introduced into FVB oocytes through pronuclear injection by the Memorial Sloan Kettering Cancer Center (MSKCC) Mouse Genetics Core Facility. Four founder lines were identified; transgene expression was only consistent in one line. This single line was used for all experiments.
ARL13B-mCherry; Centrin 2-GFP and ARL13B-mCherry; AFP-GFP were both on a mixed background of FVB and C3H. Other mouse strains used were Arl13b hnn (ref. 5), Centrin 2-GFP (ref. 8) and AFP-GFP (ref. 11). Embryos ranging from E3.5 to 14.5 as well as adult males and females for breeding between 8 weeks and 6 months and females for embryos between 8 and 10 weeks were used for this study. Animals were housed and bred under standard institutional animal care and use committee guidelines. The MSKCC Institutional Animal Care and Use Committee approved these experiments.
ESC and XEN cell derivation and differentiation. mESCs were derived as described previously 43 , maintained on mitomycin C-treated feeder cells and grown in KnockOut DMEM (Gibco) supplemented with 15% fetal bovine serum (HyClone), 2 mM L-glutamine (Gibco), 0.1 mM β-mercaptoethanol (Gibco), 0.1 mM nonessential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), 1% v/v penicillin and streptomycin (Gibco), 1,000 units LIF (Millipore), 1 µM PD0325901 and 3 µM SHIR99021 (Stemgent). XEN cells were derived as described previously 44 , maintained on 1% gelatin-coated plastic dishes and grown in RPMI1640 (pH 7.2) (Gibco) supplemented with 15% fetal bovine serum (HyClone), 2 mM L-glutamine (Gibco), 0.1 mM β-mercaptoethanol (Gibco), 0.1 mM non-essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco) and 1% v/v penicillin and streptomycin (Gibco).
XEN cells were differentiated into visceral endoderm through addition of 3 mM CHIR99021 (Stemgent) for 3 days 21 . EpiSCs were provided by M. Tomishima (MSKCC) and cultured as per ref. 45 .
TSCs were provided by A-K.H. and grown in RPMI1640 (pH 7.2) supplemented with 20% fetal bovine serum, 100 µM β-mercaptoethanol, 2 mM L-glutamine, 1 mM sodium pyruvate, 1% v/v penicillin and streptomycin (Gibco), 25 ng ml −1 FGF4 (PeproTech) and 1 µg ml −1 heparin (Sigma-Aldrich). Newly derived mESC and XEN cell lines tested negative for Mycoplasma.
Primary MEF cells were derived from E10.5 wild-type embryos by gentle pipetting in 0.5% trypsin/EDTA (Gibco). MEF cells were grown in DME supplemented with 15% bovine calf serum (BenchMark), 2 mM L-glutamine, 1% v/v penicillin and streptomycin (Gibco). To induce cilia, confluent MEFs were serum starved for 24 h. Cell lines were not authenticated by short tandem repeat profiling. Newly derived mESC and XEN cell lines tested negative for Mycoplasma.
Drug treatments. XEN cells were split 1:10 then treated for the indicated time period either immediately in 5 and 10 µM PHA-680632 (Selleckchem), 5 µM tubacin (ChemieTek) or 24 h after splitting in 250 nM alisertib (Selleckchem), 1 µM FM19G11 (Sigma), 1 µM BI2536 (Selleckchem), 2 and 20 µM N -nervonoyl D-erythro-sphingosine (C24:1) ceramide (Avanti Polar Lipids), and 20 µM proTAME (R&D Systems). All inhibitors were diluted in DMSO apart from N-nervonoyl D-erythro-sphingosine (C24:1) ceramide, which was diluted in chloroform. siRNA knockdown. XEN cells were split 1:10 and immediately transfected with siRNAs using Lipofectamine RNAiMAX (Invitrogen). AURKA knockdown was carried out using a pool of four GeneSolution siRNAs (1027416, Qiagen): Mm_AurkA_1_CACCTGTGTCGTAGCCTTCAA, Mm_AurkA_2_CAGAGTGTG TGTATAACTTAT, Mm_AurkA_3_CTCTGTCTTACTGTCATTCAA and Mm_ AurkA_4_ACCCGAGTTTATCTGATTCTA at 90 pM each. CP110 knockdown was carried out using siGENOME SMARTpool (ThermoScientific) at 90 pM.
Embryo culture. Embryos for culture were dissected in M2 culture medium (Millipore) keeping the ectoplacental cone intact, removing Reichert's membrane, then transferred to a glass-bottomed culture dish in 50% rat serum/50% DMEM/F12 and incubated at 37 • C with 5% CO 2 for 12 h in 5 µM tubacin diluted in DMSO.
Immunofluorescence staining. Cells were seeded onto fibronectin (Millipore)coated 1.5 glass coverslips (Warner Instruments), fixed in 4% paraformaldehyde (PFA) at room temperature for 5 min then 100% methanol at −20 • C for 5 min, and blocked in 0.3% Triton X-100 + 3% BSA + 5% serum in PBS.
Blastocysts were stained in U-bottomed 96 well plates coated with 1% agar/0.9% NaCl and transferred between wells with a pulled glass pipette. Blastocysts were fixed in 4% PFA for 5 min and washed three times in 0.1% Triton X-100/PBS, the zona pellucida was removed with acid Tyrode's solution for 1 min, permeabilized in 0.5% Triton X-100/100 mM glycine/PBS for 5 min, washed, and blocked in 2% goat serum/PBS for 1 h, and primary antibody was diluted in blocking solution and incubated at 4 • C overnight. Blastocysts were then washed three times in 0.1% Triton X-100/PBS, incubated with secondary antibody for 1 h, washed, and imaged in 0.1% Triton X-100/PBS on a glass-bottomed MatTek dish.
Postimplantation embryos were fixed for 1 h at room temperature in 4% PFA and washed in 0.1% Triton X-100/PBS. Embryos were blocked overnight in 0.1% Triton-X100/5% goat serum/PBS at 4 • C on a rocking platform. Primary antibody was diluted in blocking buffer and incubated overnight at 4 • C. Embryos were washed five times for 2 h in 0.1% Triton X-100/PBS, then overnight. Secondary antibody was diluted in blocking buffer and incubated for 2 h at 4 • C. Embryos were washed a further five times for 2 h in 0.1% Triton X-100/PBS, then overnight before mounting in 2% low melting point agarose on glass-bottomed MatTek dishes and sealed with VECTASHIELD Mounting Medium (Vector Labs).
For neural tube, placenta and yolk sac, embryos were fixed in 2% PFA at M E T H O D S DOI: 10.1038/ncb3091 six embryos, i-k from two embryos. Figure 2a -c shows representative data from four embryos, d-i from three embryos. Figure 3e -g shows representative data from two embryos. Figure 4a -c shows representative data from three independent experiments, d from two independent experiments, e from three independent experiments, f-w from three independent experiments and x from two independent experiments. Figure 5 shows representative data from three independent experiments. Figure 6a -d shows representative data from two independent experiments e,f from three independent experiments, g from two independent experiments, h,i from three independent experiments, j from six independent experiments and k from seven independent experiments. Supplementary Fig. 1A -F shows representative data from two independent experiments, H-L from 10 independent experiments, M from nine independent experiments and N,O from five independent experiments. Supplementary Fig. 2A -H shows representative data from three independent experiments, I from one independent experiment and J-M from two independent experiments. Supplementary Fig. 3A -F and G-K shows representative data from two independent experiments and L-S from three independent experiments. Supplementary Fig. 4A -C shows representative data from two independent experiments. Supplementary Fig. 5A -H shows representative data from two independent experiments, I-N from two independent experiments, O,P from three independent experiments, and Q-T from two independent experiments. The experiments were not randomized and the investigators were not blinded to allocation during experiments or when assessing the outcome of experiments. Mean averages are given ± s.d. Student's t-test was used for statistical analysis.
